Heart failure research
Professor David Kaye and his colleagues in the Heart Failure and Transplant service are undertaking a series of studies to investigate the causes and to develop new treatments for patients with heart failure.
Medical therapy for advanced heart failure
The care of patients with very advanced heart failure represents a significant challenge with many patients having no further treatment options available due to the presence of other complicating factors. In this context, we have developed an oral formulation of a drug (milrinone) that was previously only available intravenously. Early clinical trial experience has been positive, and this research will continue to expand, with multicentre trials planned.
Diffuse (interstitial) scarring of the heart is a major feature of many forms of heart failure, contributing to both symptoms and outcomes.
The Heart Failure research group, in collaboration with the Imaging group, has worked extensively to better understand the causes of fibrosis and the potential targets for therapy. In patients with hypertrophic cardiomyopathy, we used cardiac MRI to demonstrate that although extensive fibrosis is present in the heart, the actual rate of turnover of fibrosis is low, suggesting that anti-fibrotic therapies may require long periods of administration to provide benefit.
A study to evaluate the Corvia Medical, Inc. IASD® System II to reduce elevated left atrial pressure
VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA)
Cardiac Magnetic Resonance GUIDEd management of mild-moderate Heart Failure (CMR GUIDE HF)
Dr Shane Nanayakkara is a cardiologist and researcher currently completing a PhD in heart failure.
A/Prof Justin Mariani is a consultant cardiologist.